Tyme Technologies (NASDAQ:TYME) has earned a consensus rating of “Hold” from the six research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $8.25.
TYME has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $9.50 price target (up previously from $8.00) on shares of Tyme Technologies in a research note on Thursday, February 8th. BidaskClub upgraded Tyme Technologies from a “strong sell” rating to a “sell” rating in a research note on Tuesday, February 27th. ValuEngine upgraded Tyme Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Zacks Investment Research upgraded Tyme Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th.
Tyme Technologies stock opened at $2.34 on Wednesday. Tyme Technologies has a 12 month low of $2.01 and a 12 month high of $9.50.
In other news, CEO Steve Hoffman sold 17,986 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $3.82, for a total transaction of $68,706.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 59.60% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in TYME. Monashee Investment Management LLC purchased a new position in Tyme Technologies in the fourth quarter worth $128,000. Wells Fargo & Company MN raised its position in Tyme Technologies by 923.9% in the fourth quarter. Wells Fargo & Company MN now owns 29,180 shares of the company’s stock worth $186,000 after acquiring an additional 26,330 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new position in Tyme Technologies in the fourth quarter worth $198,000. BlueCrest Capital Management Ltd purchased a new position in Tyme Technologies in the fourth quarter worth $247,000. Finally, Family Management Corp purchased a new position in Tyme Technologies in the fourth quarter worth $702,000. Hedge funds and other institutional investors own 4.05% of the company’s stock.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company has a co-development agreement with the University of California San Francisco to evaluate SM-88 therapy in prostate cancer.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.